공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

아미노클리코사이드 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Aminoglycosides Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 866599
페이지 정보 영문
가격
US $ 4,250 ₩ 4,788,000 PDF (Single User License)
US $ 4,750 ₩ 5,352,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,760,000 PDF (Site License)
US $ 7,500 ₩ 8,451,000 PDF (Corporate License)


아미노클리코사이드 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Aminoglycosides Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 아미노클리코사이드(Aminoglycoside) 시장에 대해 조사 분석했으며, 시장 개요, 시장 역학, 시장 세분화, 지역별 시장 분석, 경쟁 구도, 주요 기업 등에 대한 체계적인 정보를 제공합니다.

목차

제1장 서론

  • 조사 성과
  • 조사의 전제조건
  • 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 질병의 치료 불능 상태
    • 세계적인 고령자 인구 증가
    • 뇌질환 유병률 증가
  • 시장 성장 저해요인
    • 아미노클리코사이드에 관련된 부작용 및 중독 반응
  • Porter's Five Forces 분석
    • 신규 참여업체의 위협
    • 구매자/소비자의 협상력
    • 공급업체의 협상력
    • 대체 제품의 위협
    • 업계내 경쟁

제5장 시장 세분화

  • 제품
    • 네오마이신(Neomycin)
    • 토브라마이신(Tobramycin)
    • 겐타마이신(Gentamicin)
    • 아미카신(Amikacin)
    • 파로모마이신(Paromomycin)
    • 스트렙토마이신(Streptomycin)
    • 카나마이신(Kanamycin)
    • 기타 아미노클리코사이드
  • 투여 경로
    • 비경구
    • 유방내
    • 국소
    • 경구
  • 용도
    • 수의학
    • 피부감염
    • 호흡기질환
    • 요로감염증(UTI)과 골반질환
    • 기타 질병
  • 지역
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • Alfasan International BV
    • Hangzhou Uniwise International Co., Ltd.
    • HuvePharma
    • Jiangxi Bolai Pharmacy Co., Ltd.
    • Kremoint Pharma Pvt. Ltd
    • Medico Remedies Pvt. Ltd
    • Medson Pharmaceuticals
    • Vega Pharma Ltd.
    • Xian Wison Biological Technology Co., Ltd.
    • Yi Chang Veterinary Medicine Factory

제7장 시장 기회 및 향후 동향

LSH 19.06.24

The Global Aminoglycosides Market was valued at USD 1,673.79 million in 2020 and is expected to reach USD 2,125.20 million by 2026, registering a CAGR of 4.11 % during the forecast period.

In the current COVID-19 pandemic, prioritizing the immunity enhancers is very important in fighting against the COVID-19. For instance, according to a research article by Nehru Sai Suresh Chalichem et al., published in Medical Hypotheses Journal June 2020, aminoglycosides found to have defense-mediated antiviral activity, which enhances immunity. Thus, consideration of aminoglycosides can be an effective class of drugs against respiratory infection as well as an immunity enhancer for the COVID-19 regimen.

The major factors driving the market growth include the growing instances of animal disease outbreaks leading to high utilization of antibiotics, rise in the aging population, and increasing prevalence of bacterial infectious diseases.

In humans and animals, the usage of aminoglycosides in the treatment of different bacterial infections is increasing due to presence of characteristics such as bactericidal, activity against staphylococci and certain mycobacteria is expected to influence market growth.

Moreover, this class of antibiotics is found to be effective even when bacterial inoculum is large, and are frequently used as a second line of defense against basic infection resistant to basic antibacterials. Increasing burden of tuberculosis is also expected to rise demand for aminoglycosides, especially in low-income countries where the incidence is alarmingly high and there is a need for aminoglycosides. For instance, As per World Health Organization (WHO), in Southeast Asia, there were around 567,000 incident cases of tuberculosis among children in 2019.

Additionally, reduction in the prescription rate of aminoglycoside antibiotics due to side effects associated with the usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade is expected to affect the market growth negatively.

Key Market Trends

Gentamicin Segment is Expected to Hold Significant Market Share Over the Forecast Period

  • Gentamicin is used in the treatment of serious infections that are caused by bacteria such as infections of the blood, lungs, bones, joints, skin and urinary tract and meningitis (infection of the membranes that surround the brain and spinal cord). Gentamicin is the agent of choice for major bacterial infections.
  • According to World Health Organization 2020, with an increasing need for extensive research on SARS-CoV-2, the diagnosis of COVID-19 infections relies heavily on the careful and aseptic collection of specimens. In order to collect specimens specialized Viral Transport Medium (VTM) required to protect the virus from environmental damage and maintain its activity with adequate sustainable transport system. Adding to that, to avoid contamination, 0.8 ml gentamicin sulfate solution was used.
  • In veterinary medicine drugs such as Gentamicin and Amikacin find maximum usage. Gentamicin is indicated in sepsis, acute/chronic renal disease, diabetes, perinatal complications, labor or neonatal complications and UTI/pyelonephritis.
  • For instance, in the year 2018, Insmed Incorporated received United States Food and Drug Administration (FDA) approval for ARIKAYCE an aminoglycoside indicated in adults who have limited or no alternative treatment options for Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen.
  • According to a research article by Recep Ozturk et al., published in World Journal of Urology January 2020, globally, Urinary tract infections are among the most frequent infections in clinical practice. Community acquired urinary tract infections (CAUTIs) affect more than 150 million people annually. Due to high burden of urinary tract infections is expected to increase use of gentamicin over the forecast period.
  • In June 2018, the University of Southern California initiated to clinical trial to assess the safety and efficacy of Gentamicin in the treatment of Junctional Epidermolysis Bullosa.
  • In both developing and developed markets, Gentamicin forms the first line of treatment for many diseases. The usage of Gentamicin is particularly high in developing regions where it is a cost-effective and efficacious drug for many infectious diseases. Thus, demand for Gentamicin is consistently growing for different bacterial related diseases, with several players using it in combinations. Thus, considering above mentioned factors, it is expected to drive market growth over the forecast period.

North America is Expected to Hold Major Market Share Over the Forecast Period

  • The major factors driving the aminoglycoside market growth include increasing incidence of bacterial infections, growing demand for early-phase diagnosis and treatment of infectious diseases, and support from the government in the prevention of infection.
  • According to a research study published in Clinical Infectious Diseases, August 2020, as per data on more than 1,700 hospitalized COVID-19 patients treated at 38 Michigan hospitals in the US from March 13 2020 to June 18, 2020, and found that more than half received early antibiotic therapy, with antibiotic use as high as 84% in some hospitals which shows a positive impact on market growth.
  • In 2018, Achaogen, Inc., received United States Food and Drug Administration (FDA) approval for aminoglycoside ZEMDRI (plazomicin) which is indicated for the treatment of patients 18 years of age or older with Complicated Urinary Tract Infections (cUTI) including Pyelonephritis.
  • As per the National Institutes of Health (NIH), in 2019, total infectious diseases funding by the National Institutes for Health in United States was around USD 6.37 billion up from USD 6.02 billion in 2018 and USD 6.02 billion in 2017, respectively. Thus, increasing funding is expected to rise demand for aminoglycosides in the prevention of infectious diseases and drives market growth.
  • According to the 2018 data published by the Centres for Disease Control & Prevention (CDC), number of deaths caused to pneumoconiosis among population aged 15 years and older in the United States was around 1,632. Thus, increasing burden of infectious diseases is expected to drive market growth as this will increase demand for aminoglycosides in the mangement of the diseases.

Competitive Landscape

The Aminoglycosides Market is moderately fragmented and competitive. The market studied is composed of a large number of players and includes both small and large pharmaceutical manufacturers. Additionally, the increasing antibiotic resistance has prompted many early-stage biotechnology enterprises to enter this market. The expiry of patent exclusivity has led to large-scale generic manufacturing of aminoglycosides, particularly in the developing region of Asia-Pacific. The key market players include Cipla Limited, Pfizer Inc., AbbVie Inc (Allergan Plc), Teva Pharmaceutical Industries Ltd, Zoetis Inc and among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Instances of Animal Disease Outbreaks Leading to High Utilization of Antibiotics
    • 4.2.2 Increase in Aging Population
    • 4.2.3 Increasing Prevalence of Bacterial Infectious Diseases
  • 4.3 Market Restraints
    • 4.3.1 Adverse and Toxic Reactions Associated with Aminoglycosides
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Neomycin
    • 5.1.2 Tobramycin
    • 5.1.3 Gentamicin
    • 5.1.4 Amikacin
    • 5.1.5 Paromomycin
    • 5.1.6 Streptomycin
    • 5.1.7 Kanamycin
    • 5.1.8 Other Aminoglycosides
  • 5.2 By Route of Administration
    • 5.2.1 Parenteral
    • 5.2.2 Intra-mammary
    • 5.2.3 Topical
    • 5.2.4 Oral
  • 5.3 By Application
    • 5.3.1 Veterinary
    • 5.3.2 Skin Infection
    • 5.3.3 Respiratory Diseases
    • 5.3.4 UTI & Pelvic Diseases
    • 5.3.5 Other Diseases
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Cipla Limited
    • 6.1.2 Pfizer Inc.
    • 6.1.3 AbbVie Inc (Allergan Plc)
    • 6.1.4 Novartis AG
    • 6.1.5 Johnson & Johnson
    • 6.1.6 Bristol Myers Squibb Company
    • 6.1.7 Vega Pharma Ltd.
    • 6.1.8 Xian Wison Biological Technology Co., Ltd.
    • 6.1.9 Yi Chang Veterinary Medicine Factory
    • 6.1.10 Insmed Incorporated
    • 6.1.11 Teva Pharmaceutical Industries Ltd
    • 6.1.12 Achaogen, Inc
    • 6.1.13 Sun Pharmaceutical Industries Limited
    • 6.1.14 Chiesi Farmaceutici
    • 6.1.15 Zoetis Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q